Tag: human signals

Research Context

MOTS-c is a mitochondrial-derived peptide encoded by the mitochondrial genome. The supplied synthesis packet includes 10 PubMed-indexed citations (one review). Packet-level notes emphasize that the evidence base is driven mainly by preclinical/mechanistic work. While the packet classifies a subset of citations as “clinical,” it provides little or no study-design or endpoint detail. Accordingly, we separate packet-classified human signals from review context and preclinical/mechanistic findings and avoid extrapolating beyond the specific disease contexts suggested by titles. Where titles are clearly mechanistic, we treat those items as preclinical even if packet classifications appear inconsistent.

Direct Answer

Based on this packet, MOTS-c research is predominantly preclinical/mechanistic. The packet classifies a limited set of citations as clinical signals, but without study-design or endpoint details, any conclusions must remain narrowly constrained to the populations and outcomes indicated by their titles. The strongest supported conclusions should stay anchored to the studied human population, endpoint, and disease context. The packet does not establish dosing, safety profiles, generalized anti-aging effects, or broad clinical utility.

Citations the packet classifies as clinical (designs not provided)

The packet flags the following as clinical. Because study designs, populations, and endpoints are not provided here, interpretation should remain tightly limited to the contexts suggested by the titles.

• pubmed:25738459 — Title indicates promotion of metabolic homeostasis and reduction of obesity and insulin resistance. Packet-classified as clinical; specific design, population, and endpoints are not provided. Do not generalize beyond the metabolic contexts in the title.
• pubmed:34798268 — Title indicates relief of hyperglycemia and insulin resistance in gestational diabetes mellitus. Packet-classified as clinical; specific to GDM. Designs and endpoints are not provided and should not be generalized outside this context.
• pubmed:33554779 — Title indicates reductions in myostatin and muscle atrophy signaling. Packet-classified as clinical; the title emphasizes signaling changes rather than clinical function or outcomes. Do not imply clinical efficacy for muscle atrophy without endpoints.

Preclinical and mechanistic evidence from packeted primary articles

In the absence of detailed methods within the packet, the following are treated as preclinical/mechanistic (species and endpoints not specified here):

• pubmed:29983246 — Title indicates that a mitochondrial-encoded peptide translocates to the nucleus to regulate nuclear gene expression under metabolic stress. Mechanistic.
• pubmed:39321430 — Title indicates suppression of ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination. Mechanistic/oncology pathway; not human clinical efficacy.
• pubmed:38790718 — Title indicates alleviation of radiation pneumonitis via an Nrf2-dependent mechanism. Preclinical/mechanistic.
• pubmed:37788894 — Title indicates mitochondrial remodelling contributing to an antiviral role during HBV infection. Preclinical/mechanistic.
• pubmed:37290680 — Title indicates suppression of ferroptosis and alleviation of acute lung injury after myocardial ischemia–reperfusion via PPARγ signaling. Preclinical/mechanistic.
• pubmed:38206815 — Title indicates interaction with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Preclinical/mechanistic.

Review Context

• A narrative review discusses MOTS-c in diabetes and aging-related diseases [pubmed:36824008]. This is background context and does not constitute primary clinical efficacy evidence within this packet.

What Is Not Established by This Packet

• Generalized anti-aging efficacy claims are not supported.
• Dosing and safety conclusions are not established here.
• Mechanistic plausibility does not establish clinical utility; direct human studies with specified endpoints and populations would be needed.
• Packet classifications may be inconsistent with article titles; consult original studies to verify human-study status and endpoints before drawing clinical inferences.

References

• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. PubMed: https://pubmed.ncbi.nlm.nih.gov/25738459/
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. PubMed: https://pubmed.ncbi.nlm.nih.gov/34798268/
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. PubMed: https://pubmed.ncbi.nlm.nih.gov/39321430/
• MOTS-c reduces myostatin and muscle atrophy signaling. PubMed: https://pubmed.ncbi.nlm.nih.gov/33554779/
• The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. PubMed: https://pubmed.ncbi.nlm.nih.gov/29983246/
• The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism. PubMed: https://pubmed.ncbi.nlm.nih.gov/38790718/
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection. PubMed: https://pubmed.ncbi.nlm.nih.gov/37788894/
• Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. PubMed: https://pubmed.ncbi.nlm.nih.gov/36824008/
• The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling pathway. PubMed: https://pubmed.ncbi.nlm.nih.gov/37290680/
• The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. PubMed: https://pubmed.ncbi.nlm.nih.gov/38206815/

Research-use-only catalog access

KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.